The question isn't really whether telehealth works for GLP-1 prescribing — millions of patients have received GLP-1 medications through telehealth platforms since 2023, and the model clearly functions. The more useful question is whether telehealth produces the same outcomes as in-person care, and in which situations each approach serves patients better.
The honest answer is nuanced. Telehealth excels at access and convenience. In-person care excels at clinical depth and physical assessment. The best approach for any individual patient depends on their specific circumstances, and increasingly, a hybrid model may be the most effective.
The Adherence Problem — and Why It Matters More Than the Visit Type
Before comparing telehealth and in-person care, it's worth understanding the context that makes this question important. The biggest challenge in GLP-1 weight loss treatment isn't getting the prescription — it's staying on the medication long enough for it to work.
Data from Prime Therapeutics shows that only about 1 in 12 patients remain on GLP-1 treatment after three years. A large proportion discontinue within the first year, often due to side effects, cost, or inadequate follow-up. Research from WeightWatchers Clinic found that patients who engaged regularly with a companion program lost significantly more weight than those who received medication alone.
This adherence challenge applies regardless of whether the initial prescription came through telehealth or in-person care. What matters more is what happens after the prescription — the quality and consistency of follow-up, side effect management, and behavioral support.
Where Telehealth Has Clear Advantages
Access
The most straightforward advantage of telehealth is that it reaches patients who might not otherwise access obesity treatment. This includes people in rural areas without nearby obesity medicine specialists, people who face stigma in traditional healthcare settings (weight bias in clinical encounters is well-documented), people with mobility limitations or demanding schedules that make in-person visits difficult, and people in states with limited specialist availability.
For these populations, the choice isn't between telehealth and in-person care — it's between telehealth and no treatment at all. In that framework, telehealth is unambiguously positive.
Convenience and consistency
Telehealth removes the friction of scheduling, traveling, and waiting for appointments. For GLP-1 treatment, which requires regular follow-up during dose titration and ongoing monitoring, reduced friction can translate into more consistent check-ins. A patient who might skip an in-person follow-up because of a long drive or a scheduling conflict may be more likely to complete a brief video check-in.
Lower barrier to starting
Obesity is undertreated in part because patients are reluctant to raise the topic with their doctors, and many primary care physicians don't proactively screen for it. Telehealth platforms specifically designed for weight management lower the psychological barrier to seeking treatment. Patients who self-select into these platforms have already acknowledged that they want help, which may improve initial engagement.
Where In-Person Care Has Clear Advantages
Physical examination
GLP-1 medications interact with several body systems, and some contraindications or risk factors are best identified through physical examination. Blood pressure measurement, abdominal assessment, thyroid palpation, and evaluation of injection site reactions (for injectable formulations) are all more reliable in person. While vital signs can be self-reported via home devices, the accuracy depends on the patient's equipment and technique.
Lab work integration
Some clinicians order baseline and follow-up lab work for patients on GLP-1 medications — metabolic panels, hemoglobin A1c, lipid profiles, and potentially thyroid function tests. In-person practices often have integrated lab services. Telehealth patients may need to visit a separate lab, which adds a step that some patients skip.
Complex medical histories
Patients with multiple comorbidities, polypharmacy, or unusual medical histories may benefit from the more comprehensive assessment that in-person care allows. GLP-1 medications have interactions with diabetes management (risk of hypoglycemia when combined with insulin or sulfonylureas), thyroid disease (boxed warning for medullary thyroid carcinoma), and gastrointestinal conditions (gastroparesis, inflammatory bowel disease). These complexities are easier to evaluate through a thorough in-person encounter.
Long-term relationship continuity
In-person care with a consistent provider builds a clinical relationship that can improve care over time. Your physician learns your patterns, preferences, and responses to treatment. While telehealth can provide continuity if you see the same clinician consistently, some platforms rotate providers in a way that fragments this relationship.
What the Emerging Data Suggests
Research specifically comparing telehealth vs. in-person GLP-1 prescribing is still limited — the large-scale, randomized studies needed to answer this question definitively haven't been completed. But the available evidence points to several trends:
Weight loss outcomes appear comparable. Studies of telehealth-based weight management programs using GLP-1 medications have shown weight loss results broadly consistent with clinical trial data. WeightWatchers Clinic reported that patients prescribed GLP-1 medications through their telehealth program lost an average of 21% of body weight at 12 months — comparable to or exceeding what clinical trials showed.
Adherence is highly variable. Both telehealth and in-person patients show significant dropout rates. The determining factor appears to be the quality and frequency of follow-up, not the modality through which it occurs. Programs that combine medication with structured behavioral support show better retention than those offering medication alone.
Patient satisfaction is generally high for telehealth. Surveys consistently show that patients value the convenience of telehealth, particularly for routine follow-ups and refill management. Satisfaction tends to be lower when patients feel the clinical interaction was superficial or rushed — which can happen in either modality but may be more common in high-volume telehealth operations.
The Hybrid Model
Increasingly, the evidence suggests that the most effective approach isn't a choice between telehealth and in-person care, but a combination of both.
A hybrid model might look like: an initial in-person evaluation that includes physical examination, lab work, and a comprehensive medical history, followed by telehealth follow-ups during dose titration (which can happen more frequently when they don't require in-person visits), periodic in-person check-ins for physical assessment, lab work, and relationship maintenance, and ongoing telehealth access for questions, side effect management, and prescription renewals between in-person visits.
This model captures the advantages of both modalities — the clinical depth of in-person care and the convenience and frequency of telehealth — while minimizing the limitations of each.
Questions to Help You Decide
How complex is your medical history? If you're managing multiple conditions, taking several medications, or have risk factors that require careful monitoring, in-person care (at least initially) may be the safer starting point.
How accessible is in-person obesity care in your area? If the nearest obesity medicine specialist is hours away, telehealth provides access that you wouldn't otherwise have. That access is more valuable than the theoretical advantage of in-person care you can't actually get.
How disciplined are you about self-monitoring? Telehealth requires patients to take more responsibility for tracking their own weight, blood pressure, and side effects. If you're comfortable with that, telehealth works well. If you rely on your provider to notice changes during an in-person visit, the remote model may miss things.
Does the telehealth platform provide meaningful follow-up? A telehealth platform with structured check-ins, responsive clinical support, and continuity of care with the same provider is a very different experience from one that's essentially a prescription mill with minimal follow-up. Evaluate the platform, not just the modality.
The Bottom Line
The telehealth vs. in-person debate for GLP-1 treatment is less about one being better than the other and more about matching the right approach to the right patient. Telehealth has expanded access to obesity treatment in ways that are genuinely transformative for many people. In-person care provides clinical depth that telehealth can't fully replicate. The best outcome for most patients probably involves elements of both.
What matters most — regardless of how you access care — is that the care itself is thorough, consistent, and focused on your long-term health rather than just the initial prescription.